ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2152 entries already.
Following the EMA’s recommendation for EU approval of sarilumab as second-line treatment for rheumatoid arthritis, French drug giant Sanofi and partner Regeneron have also been given the green light from the US FDA.
Top-Line Phase 3 data of Amgen’s/UCB’s osteoporosis antibody romosozumab in postmenopausal women suggest efficacy but uncover a new safety signal.
Luxembourg-based venture capital specialist Vesalius Biocapital has closed the first round of Biocapital III fund that aims to invest into later-stage European life sciences companies.
German Merck KGaA has developed a new genome editing tool dubbed proxy-CRISPR providing access to previously inaccessible microenviroments of the genome by modification of chromatin modifications.
Astellas Pharma Inc. has completed the acquisition of Ogeda SA (previously Euroscreen SA, Gosselies, Belgium).
Swiss Vifor Pharma has agreed to acquire shares of Cambridge-based distributor Adebia worth US$50m in order exclusivly distribute its hypoxia-inducible factor (HIF) stabiliser vadadustat to 40% of US dialysis clinics.
AstraZeneca’s anti PD-L1 antibody durvalumab has met the co-primary endpoint in non-small cell lung cancer (NSCLC) in a Phase III trial vs placebo. OS data were not yet available.
Drug makers have only until two years from now to make their drugs and packaging counterfeit-resistant. By 9 February, 2019, every prescription drug pack must carry a 2D data matrix code that can be tracked by wholesalers and pharmacists along each stage of the value chain. Additionally, each pack must be sealed with an anti-tampering device. If companies and the NMVOs that handle national databases can’t manage the task, their drugs cannot be sold after the deadline.
Until recently, aroma compounds were either sourced directly from plants or made from petrochemicals with the help of chemical synthesis processes. Now a handful of biotechnological production approaches are making headway and inroads into the key sector. There haven’t been real breakthroughs in big F&F markets yet, but biotech companies look poised to change the industry forever.
Dutch Norgine BV will take-over Merus Labs International Inc. Under the agreement, Norgine will acquire all outstanding shares for US$1.65 per share in cash.